Form 4: Allarity Therapeutics Executive Granted Restricted Stock Units

Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, was granted 118,483 restricted stock units (RSUs) in connection with his appointment.

Summary

• Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc. [ALLR], was granted 118,483 restricted stock units (RSUs) on September 30, 2024.
• The RSUs were granted in connection with his appointment as President and Chief Development Officer.
• The RSUs will vest in equal one-third installments on the first, second, and third anniversary of his appointment, contingent upon his continued relationship with the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice and indicates confidence in the executive's ability to contribute to the company's success. However, the value is tied to future performance.

Positives

• The grant of RSUs aligns the executive's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Risks

• The value of the RSUs is dependent on the future stock price of Allarity Therapeutics, which is subject to market fluctuations and company performance.
• If the executive leaves the company before the RSUs fully vest, a portion of the grant will be forfeited.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued relationship with the Issuer through each vesting date.

Management Comments

• The Reporting Person was granted 118,483 restricted stock units, or RSUs, in connection with the Reporting Person's appointment as President and Chief Development Officer of the Issuer.

Industry Context

Granting stock options and RSUs to executives is a common practice in the biotechnology industry to incentivize performance and align management's interests with shareholders.

Comparison to Industry Standards

• Executive compensation packages, including RSU grants, vary widely across the biotechnology industry depending on company size, stage of development, and individual performance.
• Comparing the size and vesting schedule of this RSU grant to similar companies like Xometry, Inc. and Rocket Lab USA, Inc. would provide a better understanding of its competitiveness.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning management's interests with their own.
• Employees may see the grant as a sign of the company's commitment to attracting and retaining talent.

Key Dates

Keywords

Allarity Therapeutics, RSU, Restricted Stock Units, Executive Compensation, Jeremy R. Graff, Form 4